Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
- Jing Yu†1Email author,
- Yue Zhang†1,
- Lai-Han Leung2,
- Lian Liu1,
- Fan Yang1 and
- Xiaojun Yao2Email author
© The Author(s). 2016
Received: 12 August 2016
Accepted: 8 October 2016
Published: 18 October 2016
Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the present study, we aimed to evaluate the efficacy and safety of angiogenesis inhibitors in advanced GC. We searched published randomized controlled trials (RCTs) comparing angiogenesis inhibitors with non-angiogenesis inhibitors for the treatment of GC. MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched. The extracted data on progression-free survival (PFS) and overall survival (OS) were measured in terms of hazard ratios (HR) and corresponding 95 % confidence intervals (CIs). In addition, risk ratios (RR) and corresponding 95 % CIs were pooled for objective response rate (ORR), disease control rate (DCR), and risk of adverse events (AEs). Ten RCTs involving 2786 patients were included. Compared with non-angiogenesis inhibitor-containing regimens, angiogenesis inhibitor-containing regimens resulted in a significant improvement in OS (HR 0.80, 95 % CI 0.69–0.93, P = 0.004), prolonged PFS (HR 0.66, 95 % CI 0.51–0.86, P = 0.002), and superior ORR (RR 1.34, 95 % CI 1.09–1.65, P = 0.005) and DCR (RR 1.37, 95 % CI 1.17–1.61, P = 0.0001). Angiogenesis inhibitors were associated with a greater number of AEs, but most of these were predictable and manageable. However, hand-foot syndrome, diarrhea, and gastrointestinal (GI) perforation were significantly increased in patients treated with angiogenesis inhibitors. In summary, angiogenesis inhibitor-containing regimens were superior to non-angiogenesis inhibitor-containing regimens in terms of OS, PFS, RR, and DCR in patients with advanced GC.
Gastric cancer (GC) is the fifth most common malignancy worldwide and is the third leading cause of cancer deaths in both sexes, accounting for 723,000 deaths (8.8 % of the total), with the highest estimated mortality rates in East Asia and the lowest in North America [1–3]. Despite a significant decline in incidence worldwide over the last few decades, unfortunately, most GC patients are diagnosed at an advanced stage with 5-year overall survival (OS) rates for all stages combined generally below 30 %. Palliative systemic chemotherapy usually represented by a platinum-based doublet is the mainstay of treatment in advanced stages. The addition of a third drug such as an anthracycline or a taxane has been shown to improve response rate and provide modest survival benefits at the cost of significant toxicity. Progress in understanding GC cancer biology has led to the development of treatment targeting the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER-2), and angiogenesis, which has changed the therapeutic paradigm of GC.
Recent studies have shown that angiogenesis in GC is a key step in metastasis. It has been confirmed that the vascular endothelial growth factor (VEGF) family is a crucial mediator of angiogenesis . Approximately 50 % of GCs express VEGF, and the overexpression of VEGF-A and VEGF-D in GC is associated with a poor prognosis [4, 5]. Two categories of agents have been developed to target this family: antibody-based agents and VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) [6–8].
Many clinical trials have demonstrated that GC patients can benefit from angiogenesis inhibitors [9–14]. Ramucirumab (a type of monoclonal antibody) or apatinib (a type of TKI), which binds to VEGFR-2, are reported to increase progression-free survival (PFS) and OS in patients treated with one or two previous lines of therapy [9–11, 13]. However, many phase I/II studies of anti-angiogenic TKIs do not show satisfactory outcomes when added to chemotherapy [15–21]. The major studies of angiogenesis inhibitors for gastric cancer were showed in Additional file 1: Table S5. Therefore, the overall efficacy and safety of anti-angiogenic agents in GC are still unknown. In this study, we performed an updated meta-analysis to summarize the efficacy and safety of angiogenesis inhibitors in patients with advanced GC.
Materials and methods
Definition of angiogenesis inhibitors
We defined angiogenesis inhibitors as those drugs which targeted VEGF and its receptors, which are the key mediators of angiogenesis.
Studies which met the following criteria were included: (1) patients must be cytologically or pathologically confirmed as having GC at a clinically advanced stage; (2) randomized controlled trials (RCTs) comparing angiogenesis inhibitors with non-angiogenesis inhibitors were deemed eligible; (3) one or more of the following were reported in the trials: overall response rate (ORR) (the sum of complete [CR] and partial responses [PR]), disease control rate (DCR) (the sum of CR, PR and stable disease [SD]), PFS, OS, and adverse events.
Two independent investigators extracted data from the included studies on the basis of PRISMA . When the two investigators disagreed, a third investigator participated in the discussion to resolve the disagreement. Information collected from these trials included the first author, year of publication, study design, number of patients, median age, ECOG performance status, therapeutic regimen, drug doses, and outcomes. Clinical outcomes collected from the trials included median PFS and OS, hazard ratios (HR) for OS and PFS and their 95 % confidence intervals (CIs), DCR and ORR, risk ratios (RR) for DCR and ORR, and their 95 % CIs, numbers, and rate of each type of adverse event stratified by severity. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and classified as a CR, PR, SD, or progressive disease (PD). ORR was defined as CR plus PR and DCR was defined as ORR plus SD.
The risk of bias in each study was assessed using the Cochrane Collaboration tool. The following evaluation domains were assessed accordingly: randomization sequence generation, allocation concealment, blinding of participants and study personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other biases. The risk of each domain was rated as high risk, unclear risk, or low risk according to the match level between information extracted and evaluation criteria.
A statistical analysis was conducted, and forest plots were performed using Review Manager 5.3. RRs and their 95 % CIs were calculated for DCR, ORR, and grade 3 and 4 toxicity as dichotomous outcomes. HRs were summarized and their corresponding standard errors were computed to analyze the time-to-event data as generic inverse variance outcomes. The inverse variance algorithm and Mantel-Haenszel algorithm were used. Heterogeneity between studies was assessed with Cochrane’s X 2 statistics and the inconsistency statistic (I 2). We considered I 2 < 50 % as low-level heterogeneity and I 2 > 50 % as significant heterogeneity. A fixed-effect model was used when I 2 < 50 % and a random-effect model was used when I 2 > 50 %. P values <0.05 were regarded as statistically significant in all included studies.
Characteristics of the included studies
Characteristics of the included studies
No. of patients
Median age (years)
Charles S. Fuchs
Ram + BSC
Placebo + BSC
P = 0.76
P < 0.0001
Ram + PTX
Placebo + PTX
P < 0.0001
P = 0.0001
Ram + mFOLFOX6
Placebo + mFOLFOX6
P = 0.008
P = 0.1695
P < 0.001
Bev + CDP + Cap
Placebo + CDP + Cap
P = 0.0315
Bev + CDP + Cap
Placebo + CDP + Cap
P = 0.35
Markus Hermann Moehler
Sunitinib + FOLFIRI
Placebo + FOLFIRI
Sunitinib + docetaxel
TSU-68 + S-1/CDDP
Assessment of methodological quality
We critically appraised the methodological quality of the included studies in accordance with the Cochrane Collaboration Risk of Bias Tool. All included trials were rated as low bias risk in randomization, as the authors stated the principles of randomization in detail. Other bias sources were not identified. The graphical results of methodological quality are shown in Fig. 2.
Overall survival (OS) and progression-free survival (PFS)
Overall response rate (ORR) and disease control rate (DCR)
RR of grade ≥3 adverse events in patients with advanced gastric cancer treated with angiogenesis inhibitors
Grade ≥3 adverse events
No. of trials
RR (95 % CI)
0.86 (0.61, 1.22)
0.94 (0.48, 1.82)
0.91 (0.55, 1.50)
0.68 (0.46, 1.00)
1.66 (1.11, 2.50)
0.77 (0.53, 1.11)
0.91 (0.44, 1.88)
1.23 (0.61, 2.48)
1.74 (0.96, 3.12)
1.53 (0.99, 2.37)
2.83 (1.57, 5.11)
1.06 (0.30, 3.79)
1.59 (1.01, 2.51)
GC is one of the most common malignant tumors of the digestive tract worldwide. With the development of therapeutic strategies, the survival time of GC patients has significantly increased over the past 20 years. However, the prospects for the treatment of GC are not optimistic. Chemotherapy is currently the main treatment for advanced GC; however, there is no standard first-line chemotherapy regimen for advanced GC. Moreover, traditional chemotherapy has reached an efficacy plateau. Therefore, it is necessary to identify a more effective treatment for advanced GC.
In the last 10 years, the rapid development of molecular biology has provided new directions for the treatment of GC. Many studies on immunotherapy and anti-angiogenic therapy are underway . For example, the results of KEYNOTE-012 and KEYNOTE-028 indicated that pembrolizumab, a type of anti-PD-1 antibody, may be a promising agent in pretreated and PD-L1-positive advanced GC. However, there is still a long way to go before patients can benefit from this treatment. Among the novel target treatment strategies, the most widely studied, the most extensive, and the most in-depth is the study of angiogenesis. The angiogenic pathway modulated by the VEGF family has been extensively studied in many tumors . Angiogenesis contributes to the progression, invasion, and metastasis of malignancy and the importance of anti-angiogenesis therapy in inhibiting malignant tumor growth has been confirmed. Targeting the VEGF pathway in GC started to receive more attention when the results from phase III trials confirmed its efficacy in inducing superior survival outcome beyond standard therapy [9, 10, 13]. Ramucirumab, a monoclonal antibody, can selectively bind to VEGFR-2 and block the downstream effects of the VEGF pathway in angiogenesis. The REGARD  and RAINBOW  studies reported that advanced GC patients may benefit from treatment with ramucirumab (HROS 0.776, 95 % CI 0.603–0.998, P = 0.047, HROS 0.807, 95 % CI 0.678–0.962, P < 0.0001, respectively, and HRPFS 0.483, 95 % CI 0.376–0.620, P < 0.0001, HRPFS 0.635, 95 % CI 0.536–0.752, P < 0.0001, respectively). The survival benefits in the REGARD and RAINBOW studies led to the approval of ramucirumab by the FDA for the treatment of advanced GC. Apatinib, a small molecule oral TKI, can inhibit the intracellular function of VEGFR by blocking the receptors of tyrosine kinases expressed by endothelial cells. A phase II  and phase III  trial explored the effects of apatinib in patients with advanced GC and the results showed that the patients benefited from apatinib treatment. Bevacizumab, a monoclonal antibody, can bind VEGF-A ligand, thus inhibiting VEGF-mediated angiogenesis. The results of the AVAGAST  study showed that bevacizumab can improve ORR (HR 8.61, 95 % CI 0.6–16.6, P = 0.0315) and prolong PFS (HR, 0.80; 95 % CI 0.68–0.93, P = 0.0037), but there was no significant difference in OS (HR 0.87, 95 % CI 0.73–1.03, P = 0.1002) when compared with the placebo. In addition, the outcomes of the AVATAR  study were similar to those of the AVAGAST study.
Fontana et al.  summarized the clinical efficacy of bevacizumab and ramucirumab in advanced GC and discussed the results of clinical trials but paid little attention on other angiogenic inhibitors, such as apatinib and sunitinib. Aprile et al.  mainly focused on the current status of novel angiogenesis inhibitors in advanced GC, the underlying biology, their mechanism of action, and recent clinical trial results. They suggested that VEGFR-2 plays a key role in GC, and VEGFR-2 blockade may be associated with improved outcomes. Future efforts in translational research should aim to clarify which patients may benefit from the anti-angiogenic therapy. The aforementioned reviews extensively describe the major clinical results of the angiogenic inhibitors, their efficiency and disadvantages in advanced GC. However, they are all narrative reviews and may lead to a number of methodological flaws without a clear and objective methods section. Furthermore, there is still controversy regarding the effects of angiogenesis inhibitors on advanced GC. Hence, we performed this updated meta-analysis to provide valuable clues for the clinical application of angiogenesis inhibitors.
According to the current results, regimens containing angiogenesis inhibitors showed substantial improvements in OS (HR 0.80, 95 % CI 0.69–0.93, P = 0.004, Fig. 3a), PFS (HR 0.66, 95 % CI 0.51–0.86, P = 0.002, Fig. 3b), ORR (HR 1.34, 95 % CI 1.09–1.65, P = 0.005, Fig. 6b), and DCR (HR 1.37, 95 % CI 1.17–1.11, P = 0.0001, Fig. 6a) compared with regimens without angiogenesis inhibitors. Subgroup analyses showed that OS was significantly improved following treatment with angiogenesis inhibitor monotherapy (HR 0.61, 95 % CI 0.42–0.89, P = 0.01, Fig. 4a) or combined with chemotherapy (HR 0.88, 95 % CI 0.79–0.97, P = 0.01, Fig. 4b) when compared with placebo and chemotherapy alone. However, angiogenesis inhibitor monotherapy was unable to prolong PFS (HR 0.86, 95 % CI 0.71–1.03, P = 0.1, Fig. 5a) in patients with advanced GC. The reason may be the anti-VEGF-based drugs combined with chemotherapy can prolong PFS (HR 0.82, 95 % CI 0.71–0.93, P = 0.003), while anti-VEGFR-2 and multiple tyrosine kinase receptor inhibitors combined with chemotherapy failed to improve PFS (HR 0.92, 95 % CI 0.65–1.03, P = 0.63). With regard to the line of treatment, the efficacy of angiogenesis inhibitor therapy may be different in the first-line and ≥ the second-line setting. Significant PFS (HR 0.50, 95 % CI 0.34–0.73, P = 0.0004, Fig. 5d), OS (HR 0.71, 95 % CI 0.58–0.88, P = 0.002, Fig. 4d), ORR (RR 1.75, 95 % CI 1.36–2.25, P < 0.0001, Fig. 8d), and DCR (RR 1.81, 95 % CI 1.27–2.58, P = 0.001, Fig. 7d) benefits were observed in ≥ the second-line setting. However, there were ORR (RR 1.16, 95 % CI 1.00–1.33, P = 0.04, Fig. 8c) and DCR (RR 1.13, 95 % CI 1.02–1.26, P = 0.02, Fig. 7c) gains, but no OS (HR 0.92, 95 % CI 0.80–1.06, P = 0.23, Fig. 4c) and PFS (HR 0.87, 95 % CI 0.75–1.01, P = 0.08, Fig. 5c) benefits in the first-line setting. This may be due to the results of the most RCTs showed no significant survival benefits regarding OS and PFS, which included in this meta-analysis. With respect to the anti-angiogenic drug class, subgroup analysis showed that anti-VEGFR-2 and multiple tyrosine kinase receptor inhibitor treatment was more efficacious than anti-VEGF treatment in terms of OS, PFS, ORR, and DCR. One possible explanation is the differences in the targets of the angiogenesis inhibitors. Anti-VEGFR-2 and multiple tyrosine kinase receptor inhibitor drugs selectively bind to VEGFR-2, which plays a key role in the VEGF/VEGFR pathway. Anti-VEGF drugs only bind to VEGF-A and thus cannot block other members of the VEGF family binding to VEGFR-2. Another possible reason is related to the two clinical trials included in the anti-VEGF subgroup, which included patients treated with bevacizumab who had negative survival outcomes. Ramucirumab and apatinib were included in the VEGFR-2 and multiple tyrosine kinase receptor inhibitor group. The mechanistic advantage of ramucirumab, which binds to VEGFR-2 and has a long half-life, may be better than bevacizumab. In addition, the recent phase III study of apatinib , an oral small molecule VEGFR-2 TKI, in Chinese patients with advanced GC, demonstrated prolonged median OS in the apatinib arm of 195 versus 140 days in the placebo arm (HR 0.71, 95 % CI 0.54–0.94, P < 0.0001). The reason for these differences is a current challenge, and further studies may elucidate the pharmacological differences and possibly improve clinical outcome.
As the incidence of GC is region-specific, and treatment approaches are different between eastern and western countries, we divided the patients into two subgroups: the Asian group and the non-Asian group. The results show that angiogenesis inhibitors increased PFS in both Asian patients (HR 0.62, 95 % CI 0.42–0.93, P = 0.02, Additional file 2: Figure S1C) and non- Asian patients (HR 0.61, 95 % CI 0.53–0.69, P < 0.00001, Additional file 2: Figure S1D) but only improved OS in non-Asian patients (HR 0.82, 95 % CI 0.70–0.95, P < 0.007, Additional file 2: Figure S1B). Given that angiogenesis is a host mechanism, the observed differences between Asian patients and non-Asian patients may be attributed to the inherent differences in these ethnic populations. This should be confirmed in future clinical trials by focusing on the influence of racial/ethnic factors.
Another focus in the treatment of GC patients is safety and tolerability. Angiogenesis inhibitors have more adverse reactions, such as hemorrhage, hypertension, and proteinuria, and most are predictable and manageable . However, hand-foot syndrome (RR 2.83, 95 % CI 1.57–5.11, P = 0.0005), diarrhea (RR 1.66, 95 % CI 1.11–2.50, P = 0.01), and GI perforation (RR 4.10, 95 % CI 1.14–15.05, P = 0.03) were significantly increased in patients treated with angiogenesis inhibitors. VEGF is also a vital factor in angiogenesis in normal tissues. Consequently, anti-angiogenic agents can destroy the network of capillaries in healthy tissues, and this is the major reason underlying the adverse reactions of these drugs. In this meta-analysis, the safety of angiogenesis inhibitors was similar to previous results for non-small cell lung carcinoma. Gastrointestinal perforation and diarrhea are due to damage to the blood flow in normal tissues by angiogenesis inhibitors and lead to intestinal ischemia and necrosis, resulting in GI perforation and diarrhea. Hand-foot syndrome, a type of skin toxicity, is a known adverse reaction of angiogenesis inhibitors, although the mechanism of this reaction is unknown, it may be associated with the effects of angiogenesis inhibitors on endothelial cells, resulting in vascular bed degradation. The hands and feet are rich in capillaries and capillary degradation is likely to lead to abnormal sensation and changes in the skin.
Although the toxicity profiles of biologics (bevacizumab, ramucirumab) and small molecule TKIs (afatinib, sunitinib, and TSU-68) overlap but are not the same, we conducted a subgroup analysis. This analysis showed that the biologics are more likely to lead to hypertension (RR 5.87, 95 % CI 3.34–10.34, P < 0.0001, Additional file 3: Table S4), neutropenia (RR 1.56, 95 % CI 1.27–1.93, P < 0.0001, Additional file 3: Table S4), diarrhea (RR 1.83, 95 % CI 1.14–2.94, P = 0.01, Additional file 3: Table S4), and gastrointestinal perforation (RR 4.14, 95 % CI 1.14–10.09, P = 0.03, Additional file 3: Table S4), while small molecule TKIs are more likely to lead to hand-foot syndrome (RR 7.70, 95 % CI 1.83–32.39, P = 0.005, Additional file 4: Table S3) and thrombocytopenia (RR 0.68, 95 % CI 0.46–1.00, P = 0.04, Additional file 4: Table S3).
Although angiogenesis inhibitors can improve OS and PFS and achieve a better response rate in advanced GC, the clinical effect is quite different in individuals due to heterogeneity of the tumor. It is unclear which patients benefit most from angiogenesis inhibitors. In an effort to limit the toxicity and cost of therapy, a large number of basic and clinical studies need to be conducted, in order to identify biomarkers which can be used to predict efficacy and choose the most suitable patients to reduce the blindness of clinical medication.
There are many limitations in this meta-analysis. Firstly, a small number of trials were included, and there were no subgroups related to tumor pathological staging or pathological types. Moreover, the subgroup analysis included in the literature was limited to one type of angiogenesis inhibitor, and the conclusions were limited. Secondly, the differences between statistical quality, follow-up period, courses, and race in patients receiving angiogenesis inhibitors resulted in heterogeneity. Thirdly, the angiogenesis inhibitors included mainly targeted VEGF and its receptor family, thus the conclusions do not cover all types of angiogenesis inhibitors. Finally, this is a trial-level meta-analysis based on studies and not on individual patient data. Confounding variables such as patient co-morbidities, extent of disease, and differences in other possible prognostic factors could not be incorporated into this analysis. Therefore, future research should focus on high-quality studies and clinical features in patients with comprehensive evaluation, thus resulting in more standardized research and more accurate conclusions.
Anti-angiogenic treatment was better than non-anti-angiogenic treatment in terms of OS, PFS, ORR, and DCR in patients with advanced GC. Further studies are needed to explore the timing and potentially predictive biomarkers of angiogenesis inhibitors to improve the selection of patients and improve clinical benefit.
This work was supported by National Natural Science Foundation of China (Grant No. 81272615 and 81101737) and Beijing Municipal “215” High-level Health Person Foundation Project (2014-3-004).
Availability of data and material
The database supporting the conclusions of this article is included within the article.
YZ, JY, and XJY contributed to the conception and design this study. LHL and LL carried out the development of the methodology. FY and LL analyzed and interpreted the data. JY and YZ wrote the manuscript and approved the final submission of the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.View ArticlePubMedGoogle Scholar
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Ca A Cancer J Clin. 2014;64:9–29.View ArticleGoogle Scholar
- Sultana N: Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from http://globocan.iarc.fr/Default.aspx. Accessed on 31 Aug. 2014.
- Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, Vita FD, Galizia G. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. Ann Surg Oncol. 2007;15:69–79.View ArticlePubMedGoogle Scholar
- Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39:9473–84.View ArticlePubMedGoogle Scholar
- Kerbel RS. Tumor angiogenesis. New Engl J Med. 2008;358:2039–49.View ArticlePubMedPubMed CentralGoogle Scholar
- Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Dressnature Rev Drug Discov. 2004;3:391–400.View ArticleGoogle Scholar
- Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nat Int Wkly J Sci. 2005;438:967–74.Google Scholar
- Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos SL, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.View ArticlePubMedGoogle Scholar
- Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky GR, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim T, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.View ArticlePubMedGoogle Scholar
- Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219–25.View ArticlePubMedGoogle Scholar
- Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Ke Y, Wang F, Li C, Qian J. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. Bmc Cancer. 2010;10:529.View ArticlePubMedPubMed CentralGoogle Scholar
- Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–54.View ArticlePubMedGoogle Scholar
- Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;47:1511–20.View ArticlePubMedGoogle Scholar
- Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drug. 2011;29:1449–58.View ArticleGoogle Scholar
- Martin-Richard M, Gallego R, Pericay C, Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drug. 2013;31:1573–9.View ArticleGoogle Scholar
- Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Rd BA. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28:2947–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Koizumi W, Yamaguchi K, Hosaka H, Takinishi Y, Nakayama N, Hara T, Muro K, Baba H, Sasaki Y, Nishina T. Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. Brit J Cancer. 2013;109:2079–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Wainberg ZA, Lin LS, Dicarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N, Hecht JR. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Brit J Cancer. 2011;105:760–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Ramanathan RK, Ms MD, Kennecke HF, Syma Iqbal MD, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer-Am Cancer Soc. 2015;121:2193–7.Google Scholar
- Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. Am J Clin Oncol. 2011;34:443–8.View ArticlePubMedGoogle Scholar
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;7:889–96.Google Scholar
- Yi JH, Lee J, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY, Kang WK. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Brit J Cancer. 2012;106:1469–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Moehler MH, Thusspatience PC, Schmoll HJ, Hegewischbecker S, Wilke H, Albatran SE, Weissinger F, Kullmann F, Siveke JT, Kanzler S. FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: a randomized placebo-controlled multicentric AIO phase II trial. 2013.Google Scholar
- Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–76.View ArticlePubMedGoogle Scholar
- Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18:168–76.View ArticlePubMedGoogle Scholar
- Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip AP, Cohn AL. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014.Google Scholar
- Goel G, Sun W. Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade. J Hematol Oncol. 2014;8:1–4.Google Scholar
- Goel G, Sun W. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting-its impact on clinical practice. J Hematol Oncol. 2015;8:1–3.View ArticleGoogle Scholar
- Fontana E, Sclafani F, Cunningham D. Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol. 2014;35:253–62.View ArticlePubMedPubMed CentralGoogle Scholar
- Aprile G. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Crit Rev Oncol Hematol. 2015;95:165–78.View ArticlePubMedGoogle Scholar